Boehringer Ingelheim has licensed the global rights to Zealand Pharma’s dual-acting glucagon and GLP-1 (glucagon-like peptide-1) agonists for the treatment of type 2 diabetes and obesity. The collaboration includes ZP2929, which is expected to enter clinical development in the third quarter of 2011 and which some analysts believe could attain blockbuster status owing to its potential for obesity reduction. Zealand Pharma could receive total milestone payments of up to €376 M (US$539 M) for ZP2929 and payments of up to €41 M (US$58 M) during the first 2 years of the collaboration.